GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Glioblastoma-secreted GABA contributes to the immunosuppressive environment

$432,250
Daniel Kaufman · University Of California Los Angeles · R21 · FY2024 · NS

Epigenetic Synergy Between DNMT and EZH1/2 Inhibitors for Therapy in Solid Tumors

$432,171
Scott Rothbart · Coriell Institute For Medical Research · P50 · FY2021 · CA

Protein Kinase Cz targets in Intestinal Cancer Stem Cells

$432,152
Jorge Moscat · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2014 · CA

Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer

$432,128
Kent W Mouw · Dana-Farber Cancer Inst · R01 · FY2022 · CA

HIV persistence and treatment response in Kaposi sarcoma

$432,098
Edus Houston Warren · Fred Hutchinson Cancer Center · R21 · FY2025 · CA

Regulation of Urinary Bladder Carcinogenesis and Progression by SPARC

$432,063
Neveen Said · Wake Forest University Health Sciences · R01 · FY2020 · CA

Contribution of osteocytes to the musculoskeletal effects of Multiple Myeloma

$432,059
Jesus Delgado-Calle · Univ Of Arkansas For Med Scis · R01 · FY2024 · CA

Molecular Mechanisms of Large Oncosome-Induced Prostate Cancer Progression and Metastasis

$432,034
Dolores Di Vizio · Cedars-Sinai Medical Center · R01 · FY2023 · CA

The regulation and targeting of cell survival pathways in cancer

$431,999
Joshua Lyon Andersen · Brigham Young University · R15 · FY2016 · CA

Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma

$431,993
Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2025 · CA

The role of P16Ink4a in adult skeletal muscle stem cells

$431,984
Brian Feeley · University Of California, San Francisco · R01 · FY2024 · AR

The role of P16Ink4a in adult skeletal muscle stem cells

$431,984
Brian Feeley · University Of California, San Francisco · R01 · FY2025 · AR

Nicotinamide N-Methyltransferase (NNMT) as a master regulator of cancer stroma

$431,980
Ernst Lengyel · University Of Chicago · R01 · FY2017 · CA

Monitoring Listeria in vivo using 18FDG and PET scan

$431,970
Claudia Gravekamp · Albert Einstein College Of Medicine · R21 · FY2024 · CA

Rewired Metabolism and Immunosuppression in MYCN-driven Neuroblastoma

$431,968
Eveline Barbieri · Baylor College Of Medicine · R01 · FY2024 · CA

Targeting LSD1 to prevent therapy-induced transdifferentiation in BRAF mutant colorectal cancer

$431,920
Heather M O'Hagan · Indiana University Indianapolis · R01 · FY2024 · CA

Systematic characterization of cancer variants using single-cell functional genomics

$431,914
Thomas Maxwell Norman · Sloan-Kettering Inst Can Research · R33 · FY2023 · CA

Targeted inhibition of eIF5Ahpu suppresses tumor growth and M2-like TAM polarization in oral cancer

$431,912
Anh D Le · University Of Pennsylvania · R01 · FY2024 · DE

Targeting immune suppressive microenvironment in ATC

$431,902
James A Fagin · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA

Targeting immune suppressive microenvironment in ATC

$431,902
James A Fagin · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA

Three-dimensional organoid models to study breast cancer progression

$431,871
Shilpa Sant · University Of Pittsburgh At Pittsburgh · R37 · FY2019 · CA

Expression of recombinant Fc receptors by engineered NK cells to enhance cancer cell killing

$431,818
Bruce K Walcheck · University Of Minnesota · R01 · FY2023 · CA

Expression of recombinant Fc receptors by engineered NK cells to enhance cancer cell killing

$431,814
Bruce K Walcheck · University Of Minnesota · R01 · FY2022 · CA

Metabolic Barriers to T Cell Activation in Clear Cell Renal Cell Carcinoma

$431,810
Jeffrey C Rathmell · Vanderbilt University Medical Center · R01 · FY2019 · CA

NGTC - UCL

$431,742
Martin Pule · University College London · OT2 · FY2023 · CA